Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial Authors: Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li, Yu Cao, Jing Zhao, Liyuan Zhao, Wei Chen Published: 2026 ABSTRACT SummaryGZR18 is a long-acting glucagon-like peptide-1 receptor agonist that is under development for the treatment of type 2 diabetes mellitus (T2DM). In this randomized, double-blind, placebo-controlled phase 1b/2a trial in Chinese adults with T2DM, the safety and efficacy of once-weekly GZR18 are evaluated using different dose-titration regimens in two separate parts: Part A (0.5–4 mg over 26 weeks) and Part B (1.5–13 mg over 23 weeks). Overall, 72 participants are enrolled, of whom 62 complete the trial. GZR18 significantly reduces glycated hemoglobin (HbA1c) in both parts (Part A: −1.32% for GZR18 versus 0.86% for placebo; Part B: −1.81% for GZR18 versus 0.12% for placebo). Improvements in body weight and other metabolic parameters are also observed. GZR18 is safe and well tolerated, with mostly mild-to-moderate gastrointestinal adverse events; no severe hypoglycemia or treatment-related serious adverse events occurred. These findings support further development of GZR18 in larger, longer-term trials. The trial is registered at ClinicalTrials.gov (NCT06256523).Keywords: GLP-1 receptor agonist, HbA1c, type 2 diabetes, weight control, bofanglutide, GZR18 Introduction Diabetes is a global health challenge, affecting over 589 million individuals worldwide as of 2024, with projections indicating that this number may reach 853 million by 2050.1 Of these, type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, progressive beta-cell dysfunction, and dysregulation of multiple metabolic pathways, including lipid and protein metabolism. These abnormalities contribute to elevated blood glucose levels and an increased risk of complications such as cardiovascular disease, nephropathy, and neuropathy.2 While glycemic control remains critical for reducing associated risks, growing evidence emphasizes the need for a comprehensive therapeutic approach targeting the underlying metabolic dysregulation to achieve effective disease management.3 In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as pivotal agents in T2DM management. This is primarily due to their ability to promote glucose-dependent insulin secretion and inhibit glucagon release, thereby achieving effective glycemic control. Substantial clinical trials have demonstrated that GLP-1 RAs reduce glycated hemoglobin (HbA1c) levels by 1.5%–2.0%, with 30%–40% of participants achieving the HbA1c target of less than 7%.4 This reduction was comparable to the efficacy of insulin therapy; however, GLP-1 RAs were associated with a significantly lower risk of hypoglycemia.4,5 This provides a distinct advantage, particularly for patients who are insulin sensitive or experience significant blood glucose variability, making GLP-1 RAs a favorable option for many patients with T2DM.6 Beyond their role in glycemic control, emerging research has highlighted the comprehensive therapeutic potential of GLP-1 RAs on other key aspects of T2DM pathophysiology, including benefits in body weight reduction, cardiovascular health, and other metabolic comorbidities.7,8 By delaying gastric emptying and suppressing appetite, GLP-1 RAs have demonstrated efficacy in treating overweight and obesity.9 Furthermore, they have shown cardiovascular protection by improving endothelial function and have been associated with reduced cardiovascular events and mortality in high-risk patients with T2DM.10,11 Given their additional benefits in promoting weight loss and cardiometabolic improvements, GLP-1 RAs are increasingly recommended for the treatment of T2DM and its associated comorbidities.12 GZR18 (bofanglutide), a long-acting GLP-1 RA, was developed to improve glycemic control in patients with T2DM. A distinguishing feature of GZR18 is its incorporation of structural modifications that allow for a long duration of action. These modifications not only stabilize GZR18 against degradation by dipeptidyl peptidase-4 enzymes through specific amino acid alterations in the GLP-1 backbone but also extend its half-life by covalently attaching a 22-carbon fatty diacid side chain to the GLP-1 backbone, which facilitates reversible binding to human serum albumin and subsequently delays drug absorption and clearance.13 Preclinical studies of GZR18 in diabetic and obese animal models have demonstrated notable glucose-lowering and weight-loss effects.13 In the first-in-human phase 1 trial, GZR18 demonstrated a favorable safety and tolerability profile among healthy participants from both American and Chinese populations.14 The present phase 1b/2a trial was designed to further assess the safety and glucose-lowering effect of GZR18 as monotherapy versus placebo in Chinese patients with T2DM. Results Participant disposition, demographics, and baseline characteristics Between July 20, 2022, and September 28, 2023, a total of 186 participants were screened (Figure 1). Of these, 72 were enrolled, with 36 randomized and treated in each part. The trial completion rates were 88.9% (32/36) in Part A and 83.3% (30/36) in Part B. The primary reason for trial discontinuation was the withdrawal of consent, which occurred in 5.6% (2/36) of participants in Part A and 8.3% (3/36) in Part B. All 36 treated participants in each part were included in the safety analysis set. The full analysis set (FAS) and pharmacokinetic analysis set comprised 36 participants in Part A and 35 in Part B; one participant in Part B was excluded due to sudden death without post-treatment efficacy/pharmacokinetic data. Demographics and baseline characteristics were well balanced between treatment groups in each part (Table 1). Overall design of the trial The flow diagram illustrates the disposition of participants screened and randomized in Part A and Part B. Table 1Demographics and baseline characteristicsPart A (N = 36)Part B (N = 35)GZR18 (n = 27)Placebo (n = 9)GZR18 (n = 26)Placebo (n = 9)Age, years53.6 (11.5)53.0 (10.1)54.8 (10.1)49.7 (11.6)Gender (male), n (%)11 (40.7)6 (66.7)18 (69.2)5 (55.6)Gender (female), n (%)16 (59.3)3 (33.3)8 (30.8)4 (44.4)Han nationality, n (%)24 (88.9)9 (100.0)24 (92.3)9 (100.0)Weight, kg72.9 (14.2)77.5 (16.6)76.1 (13.0)72.2 (13.1)Waist circumference, cm94.8 (10.2)95.1 (12.7)95.0 (9.5)91.2 (6.5)BMI, kg/m226.8 (3.4)27.0 (4.2)27.1 (3.8)25.8 (2.8)Duration of diabetes, years3.2 (3.5)2.6 (2.4)4.1 (4.5)4.6 (3.7)HbA1c, %8.0 (0.7)8.0 (0.7)8.3 (0.7)8.2 (0.6)FPG, mmol/L9.6 (2.0)10.3 (1.7)9.8 (1.7)9.9 (1.3)GA, %20.3 (2.9)21.3 (2.4)21.7 (3.7)21.4 (2.7)TC, mmol/L5.0 (0.9)4.6 (0.6)5.1 (1.1)5.7 (1.2)LDL-C, mmol/L3.1 (0.6)3.0 (0.6)3.2 (0.9)3.6 (1.0)HDL-C, mmol/L1.3 (0.4)1.2 (0.2)1.3 (0.5)1.3 (0.2)TG, mmol/L1.9 (1.0)1.9 (0.7)2.0 (1.0)2.6 (1.5)Data are displayed as n (%) or mean (SD), FAS population.One patient in Part B without any post-use efficacy data was excluded from the FAS population.BMI, body mass index; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; GA, glycated albumin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; FAS, full analysis set. Demographics and baseline characteristics Data are displayed as n (%) or mean (SD), FAS population. One patient in Part B without any post-use efficacy data was excluded from the FAS population. BMI, body mass index; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; GA, glycated albumin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; FAS, full analysis set. Safety profile In Part A, treatment-emergent adverse events (TEAEs) were reported in 96.3% (26/27) of participants in the GZR18 group (149 events) and 100.0% (9/9) in the placebo group (31 events); the majority of TEAEs were grade 1 or 2 in severity. Grade 3 or higher TEAEs included dizziness (grade 3) and colorectal adenoma (grade 5). Of these, dizziness was considered by the investigator to be related to GZR18, while colorectal adenoma was considered as a serious adverse event (SAE) due to the resulting hospitalization; both events recovered/resolved. TEAEs leading to trial discontinuation occurred in three GZR18-treated participants: one with headache, chest pain, and abdominal discomfort; one with palpitation; and one with dizziness; all were considered possibly related to GZR18 by the investigator. Gastrointestinal adverse events (AEs) were the most common TEAEs, reported in 25.9% (7/27) of participants in the GZR18 group and 22.2% (2/9) in the placebo group, with nausea and diarrhea being the most common symptoms (11.1% [3/27] for both in the GZR18 group versus 11.1% [1/9] for both in the placebo group). These events were transient and manageable. Two hypoglycemic episodes (one level 1 and one level 2) occurred in two GZR18-treated participants. No injection site reactions were reported in either group (Table 2). Table 2Summary of adverse eventsPart A (N = 36)Part B (N = 36)GZR18 (n = 27)Placebo (n = 9)GZR18 (n = 27)Placebo (n = 9)TEAE26 (96.3) 1499 (100) 3125 (92.6) 1698 (88.9) 31Grade 3 or higher TEAE2 (7.4) 20 (0) 03 (11.1) 51 (11.1) 1IP-related TEAE16 (59.3) 422 (22.2) 523 (85.2) 1163 (33.3) 3TEAE leading to trial discontinuation3 (11.1) 50 (0) 03 (11.1) 50 (0) 0SAE1 (3.7) 10 (0) 02 (7.4) 20 (0) 0IP-related SAE0 (0) 00 (0) 00 (0) 00 (0) 0Hypoglycemia2 (7.4) 20 (0) 00 (0) 00 (0) 0Gastrointestinal AEs7 (25.9) 92 (22.2) 215 (55.6) 422 (22.2) 3Nausea3 (11.1) 31 (11.1) 110 (37.0) 130 (0) 0Diarrhea3 (11.1) 41 (11.1) 18 (29.6) 162 (22.2) 2Vomiting0 (0) 00 (0) 03 (11.1) 71 (11.1) 1Injection site reaction0 (0) 00 (0) 03 (11.1) 251 (11.1) 1Data are displayed as n (%) E, SS population. n = number of participants with events (%); E = number of events.TEAE, treatment-emergent adverse event; IP, investigational product; AE, adverse event; SAE, serious adverse event; SS, safety analysis set. Summary of adverse events Data are displayed as n (%) E, SS population. n = number of participants with events (%); E = number of events. TEAE, treatment-emergent adverse event; IP, investigational product; AE, adverse event; SAE, serious adverse event; SS, safety analysis set. In Part B, TEAEs were reported in 92.6% (25/27) of participants in the GZR18 group (169 events) and 88.9% (8/9) in the placebo group (31 events); the majority were grade 1 or 2 in severity. Grade 3 or higher TEAEs included enteritis (grade 3), hypertriglyceridemia (grade 4), and sudden death (grade 5) in the GZR18 group and increased blood triglyceride (grade 3) in the placebo group. Among these, enteritis and sudden death were considered SAEs due to hospitalization/death, but none were considered to be related to GZR18 by the investigator. TEAEs leading to trial discontinuation occurred in three GZR18-treated participants: one with chest discomfort, nausea, and gastrointestinal disorder; one with enteritis; and one with sudden death. Of these, only nausea and gastrointestinal disorder were considered to be related to GZR18 by the investigator. Gastrointestinal AEs were the most frequent TEAEs, reported in 55.6% (15/27) of participants in the GZR18 group and 22.2% (2/9) in the placebo group. Consistent with Part A, nausea and diarrhea were the most common symptoms, occurring in 37.0% (10/27) and 29.6% (8/27) of GZR18-treated participants, respectively, compared to 0 (0/9) and 22.2% (2/9) in the placebo group. The incidence of gastrointestinal AEs was more frequently observed during early dose escalation, peaking at 5 mg and gradually declining thereafter. No hypoglycemia was reported. Injection site reactions (all grade 1) were reported in three participants receiving GZR18 and one receiving placebo (Table 2). Mild and transient treatment-related cardiac disorders were reported in two participants receiving GZR18 (one with palpitations in Part A and one with sinus tachycardia in Part B). No elevations in lipase or amylase exceeding three times the upper limit of normal were observed in either part during the trial, and no cases of investigator-suspected pancreatitis were reported. There were no reports of thyroid tumors, neoplasms, or C-cell hyperplasia. In both parts, GZR18 exhibited similar immunogenicity profiles, with 11.1% (3/27) of participants in both Part A and Part B testing positive for anti-GZR18 antibodies; no neutralizing antibodies were detected. Changes in glycemic parameters In Part A, GZR18 treatment improved glycemic control. In the primary analysis using the modified FAS population, the mean change in HbA1c from baseline to week 26 was −1.32% in the GZR18 group compared to 0.86% in the placebo group (estimated treatment difference [ETD] of −2.18%, 95% confidence interval, [CI] −2.79, −1.57]) (Figure 2A). A sensitivity analysis using mixed-model for repeated measures (MMRM) model in the FAS population yielded results consistent with the primary analysis, confirming the robustness of these findings (Table S1). During the treatment period at the highest dose of 4.0 mg from weeks 14 to 26, HbA1c levels continued to decrease in the GZR18-treated participants, with a mean change of −0.31% versus 0.27% for placebo (ETD of −0.58% [95% CI, −1.13, −0.03]) (Table S2). After 26 weeks, 55.6% (15/27) and 44.4% (12/27) of participants in the GZR18 group achieved an HbA1c below 7.0% and 6.5% or lower, respectively, whereas no participants in the placebo group reached either target (Figure 2B). Fasting plasma glucose (FPG) decreased by 1.51 mmol/L in the GZR18 group, compared to an increase of 0.93 mmol/L in the placebo group (ETD of −2.44 mmol/L [95% CI, −5.42, 0.54]) (Figure 2C). The change in glycated albumin (GA) from baseline to week 26 was −3.17% with GZR18 and 2.09% with placebo (ETD of −5.26% [95% CI, −7.56, −2.97]) (Figure 2D). Changes from baseline in glycemic parameters in Part A (A) Change in HbA1c from baseline to week 26. (B) Proportion of participants achieving HbA1c targets. (C) Change in FPG from baseline to week 26. (D) Change in GA from baseline to week 26. Data in (A, C, and D) are plotted as mean ± SE for changes from baseline to week 26 in the modified FAS population (GZR18: n = 21; placebo: n = 8). Estimated treatment differences are shown as mean (95% CI). Data in (B) are calculated as the number of participants achieving the respective target at week 26 divided by the total number of participants in the FAS population (GZR18: n = 27; placebo: n = 9). HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; GA, glycated albumin; FAS, full analysis set. See also Figure S2 and Tables S1, S2, and S4. In Part B, GZR18 treatment achieved effective glycemic control at the target dose of 13 mg. In the primary analysis using the modified FAS population, the mean HbA1c reduction from baseline to week 23 was 1.81%, compared to an increase of 0.12% in the placebo group (ETD of −1.93% [95% CI, −2.91, −0.95]) (Figure 3A). A sensitivity analysis using MMRM model in the FAS population yielded results consistent with the primary analysis, confirming the robustness of these findings (Table S3). After 23 weeks, 57.7% (15/26) and 46.2% (12/26) of the participants in the GZR18 group achieved an HbA1c below 7.0% and 6.5% or lower, respectively, whereas no participants in the placebo group reached either target (Figure 3B). FPG decreased by 2.95 mmol/L in the GZR18 group, compared to a reduction of 0.16 mmol/L in the placebo group (ETD of −2.80 mmol/L [95% CI, −4.11, −1.48]) (Figure 3C). The change in GA from baseline to week 23 was −4.90% with GZR18 and −0.95% with placebo (ETD of −3.95% [95% CI, −7.29, −0.60]) (Figure 3D). Changes from baseline in glycemic parameters in Part B (A) Change in HbA1c from baseline to week 23. (B) Proportion of participants achieving HbA1c targets. (C) Change in FPG from baseline to week 23. (D) Change in GA from baseline to week 23. Data in (A, C, and D) are plotted as mean ± SE for changes from baseline to week 23 in the modified FAS population (GZR18: n = 21; placebo: n = 9). Estimated treatment differences are shown as mean (95% CI). Data in (B) are calculated as the number of participants achieving the respective target at week 23 divided by the total number of participants in the FAS population (GZR18: n = 26; placebo: n = 9). HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; GA, glycated albumin; FAS, full analysis set. See also Figure S2 and Tables S3–S5. GZR18 treatment also improved self-monitoring of blood glucose (SMBG) profiles. At the end of treatment (week 26 in Part A and week 23 in Part B), the GZR18 group showed numerically greater reductions from baseline in blood glucose at all measured time points, including pre-meals, 2 h post-meals, and bedtime, compared to the placebo group (Figure S2). These reductions were particularly pronounced after meals, with changes of up to −3.94 mmol/L (ETD of −5.61 mmol/L [95% CI −8.84, −2.38]) at 2 h post-breakfast in Part A (Table S4) and −5.59 mmol/L (ETD of −7.95 mmol/L [95% CI, −12.13, −3.77]) at 2 h post-lunch in Part B (Table S5). During the trial, a total of five participants received rescue therapy: two (7.4%) in the GZR18 group and two (22.2%) in the placebo group in Part A, and one (11.1%) in the placebo group in Part B. Weight-related parameters and lipid profile At the end of treatment, participants treated with GZR18 demonstrated reductions in body weight, body mass index (BMI), and waist circumference, along with improvements in blood lipids in both Part A and Part B, with more pronounced effects observed in Part B. The outcomes from Part A are presented in Table S6. In Part B, participants treated with GZR18 achieved a mean body weight reduction of 6.92 kg after 23 weeks of treatment, compared to a minimal reduction of 0.76 kg in the placebo group (ETD of −6.17 kg [95% CI, −8.92, −3.41]) (Figure 4A). The percent change from baseline in body weight was −9.25% in the GZR18 group and −1.19% in the placebo group (ETD of −8.06% [95% CI, −11.72, −4.40]) (Figure 4B). From baseline to week 23, the mean reductions in BMI and waist circumference were 2.56 kg/m2 and 5.31 cm, respectively, in the GZR18 group, compared to 0.28 kg/m2 and 1.09 cm in the placebo group (Figures 4C and 4D). Furthermore, GZR18 treatment was associated with favorable changes in lipid profiles: total cholesterol, low-density lipoprotein cholesterol, and triglycerides decreased by 0.92 mmol/L, 0.63 mmol/L, and 0.57 mmol/L, respectively, versus changes of −0.58 mmol/L, −0.44 mmol/L, and 1.10 mmol/L in the placebo group (Figure 4E). Changes from baseline in body weight-related parameters and lipid profiles in Part B (A) Change in body weight from baseline over time. (B) Percentage change in body weight from baseline to week 23. (C) Change in BMI from baseline to week 23. (D) Change in waist circumference from baseline to week 23. (E) Change in lipid profiles from baseline to week 23. Data are plotted as mean ± SE for changes from baseline to week 23 in the modified FAS population (GZR18: n = 21; placebo: n = 9). Estimated treatment differences are shown as mean (95% CI). BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; FAS, full analysis set. See also Figures S3 and S4; Table S6. Pharmacokinetics The pharmakokinetic profile of GZR18 was evaluated in both parts. In Part A, the mean trough plasma concentration of GZR18 reached 30.07 ng/mL following a single 0.5 mg dose and increased to 429.84 ng/mL after four doses of 4 mg. Thereafter, concentrations stabilized, with mean trough values of 401.70 ng/mL and 405.44 ng/mL after four and eight consecutive doses at the same dose, respectively (Figure 5A). In Part B, the mean trough plasma concentration was 72.78 ng/mL after a single 1.5 mg dose and increased to 1,210.15 ng/mL after four doses of 13 mg (Figure 5B). Plasma concentrations of GZR18 during the trial (A) Semi-logarithmic transformed mean plasma concentration-time profile of GZR18 with 0.5–4.0 mg dose escalation in Part A. (B) Semi-logarithmic transformed mean plasma concentration-time profile of GZR18 with 1.5–13 mg dose escalation in Part B. Data are plotted as mean ± SE. Error bars may not be clearly visible due to their small magnitude relative to the mean values. Discussion In this trial, GZR18 demonstrated a substantial HbA1c reduction of up to 1.81%, supporting its potential as a promising therapeutic option for patients with T2DM. Beyond glycemic control, GZR18 treatment also resulted in robust reductions in body weight and improvements in several cardiovascular and metabolic risk factors. These findings were consistent with observations from preclinical studies of GZR18 in diabetic animal models and supported the advancement of subsequent phase 2 clinical trials. Previous in vitro pharmacological studies indicated that GZR18 exhibited comparable or moderately lower bioactivity than semaglutide.13 Accordingly, Part A of the trial employed a dose-escalation regimen from 0.5 mg to 4.0 mg, mirroring the dose-escalation strategy used for semaglutide,4,15 but with a slightly higher target dose. GZR18 demonstrated favorable safety and tolerability up to the 4.0 mg dose, with no investigational product (IP)-related SAEs, and the incidence of gastrointestinal AEs was similar to that observed with placebo. Notably, a 1.32% reduction in HbA1c and a 3.82% reduction in body weight were observed after 26 weeks of GZR18 treatment (including an 8-week dose-maintenance period at 4.0 mg). Current clinical trends emphasize the use of higher doses of GLP-1 RAs to maximize therapeutic efficacy, as demonstrated by the ongoing evaluation of semaglutide at 7.2 mg dose for glycemic control and weight management, despite its approved 1 mg dose.16 Based on the favorable tolerability profile of GZR18 in the first-in-human study, where doses were escalated up to 50 μg/kg (approximately 2.5–4.0 mg) with incremental steps of 10–40 μg/kg (corresponding to approximately 0.6–0.7 mg to 2.4–2.8 mg for individuals weighing 60–70 kg),14 Part B was further designed to assess its efficacy and safety at higher doses (1.5–13 mg). This dose selection was further supported by accumulating safety data obtained from Part A. To achieve the target dose more efficiently, the dose increments in Part B were increased to 1.5–2.0 mg, compared with the 0.5–1.0 mg increments used in Part A. Throughout Part B, GZR18 maintained an acceptable safety profile, with no IP-related SAEs, grade 3 or higher TEAEs, or hypoglycemic events reported. Consistent with other known GLP-1 RAs,4,17,18,19,20,21,22,23 gastrointestinal AEs were the most frequently observed TEAEs. These events were mild or moderate, peaked at the 5 mg dose, and diminished with further dose escalation, suggesting the development of tolerance. These findings, combined with the data from the phase 1b/2a trial in overweight/obese individuals (1.5–30 mg),24 support the advancement of GZR18 into phase 2b trials in patients with T2DM (NCT06256549). This trial incorporates larger dose increments and will evaluate higher target doses up to 24 mg, a dose level not previously tested, to fully explore its therapeutic potential. Despite the relatively short treatment durations in Part A (26 weeks) and Part B (23 weeks), GZR18 demonstrated substantial HbA1c reductions of 1.32% and 1.81% (placebo-adjusted reductions: 2.18% and 1.93%), respectively, in the present trial. For context, published studies of other long-acting GLP-1 RAs such as semaglutide (0.5/1 mg)4,15 and dulaglutide (0.75/1.5 mg),23,25 have reported HbA1c reductions of approximately 1.3%–1.7% over treatment periods of 26–30 weeks in patients with T2DM. Notably, during the dose-maintenance period at 4.0 mg in Part A, HbA1c levels continued to decline in participants receiving GZR18, indicating sustained efficacy with continuous treatment. These findings suggest that GZR18 represents a promising therapeutic option for patients with T2DM. In addition to HbA1c reduction, GZR18 demonstrated significant improvements in other glycemic parameters, including reduced FPG (placebo-adjusted reductions of 2.44 mmol/L in Part A and 2.80 mmol/L in Part B) and substantially lowered postprandial glucose, as measured by SMBG, with placebo-adjusted reductions up to 5.61 mmol/L in Part A and 7.95 mmol/L in Part B. Furthermore, GZR18 achieved significant body weight reductions (mean 9.25% at 23 weeks in Part B), which is a key consideration in the management of patients with concomitant overweight or obesity. The weight-loss potential of GZR18 is further supported by findings from a separate phase 1b/2a trial in individuals with obesity without T2DM, where once-weekly GZR18 (up to 30 mg) achieved a placebo-adjusted weight reduction of 18.6% after 35 weeks.24 In the present trial, GZR18 demonstrated dose-dependent reductions in FPG and body weight across the dose ranges of 0.5–4 mg and 1.5–13 mg, respectively, with potential for further enhancement at higher plasma concentrations. Combined with the favorable safety profile observed, these findings support the investigation of even higher doses under stringent clinical monitoring and effective management of potential AEs in future clinical trials. Although this trial primarily evaluated glycemic control and safety in patients with T2DM, the potential of GZR18 may extend beyond diabetes management, a possibility supported by the well-documented cardiovascular benefits of the GLP-1 RA class.11 Liraglutide and semaglutide, for example, significantly reduced blood pressure and lipid levels while improving cardiovascular outcomes in pivotal trials such as LEADER and SUSTAIN-6.6,26 Consistent with these observations, treatment with GZR18, particularly in Part B, improved multiple cardiometabolic parameters, including waist circumference, blood lipids, and blood pressure. Specifically, systolic blood pressure showed a mean decrease of 15.4 mmHg from a baseline level of 128.8 mmHg at week 23 (Figure S3), with 64% of participants achieving a reduction exceeding 10 mmHg (data not shown). The waist-to-height ratio (WHtR) has been recognized as an indicator of cardiovascular disease risk.27 In this trial, GZR18 treatment led to a 3.24% reduction in WHtR from baseline following 23 weeks (Figure S4). Collectively, these findings suggest that GZR18 may confer cardiovascular benefits, particularly under longer treatment conditions; however, this remains exploratory and requires confirmation in dedicated cardiovascular outcome trials. In conclusion, once-weekly GZR18 was effective and well tolerated across the investigated dose regimens in Chinese patients with T2DM. GZR18 achieved significant reductions in HbA1c and body weight, along with improvements in multiple cardiovascular and metabolic risk factors. These findings support the further clinical development of GZR18 for the treatment of T2DM. Limitations of the study The present trial has several limitations. First, the relatively small sample size and short treatment duration may limit the generalizability of the findings. Notably, the final target dose in Part B was administered for only 4 weeks, which may have restricted the comprehensive assessment of safety and efficacy. Larger, longer-term trials are warranted to fully evaluate the potential of GZR18 regarding glycemic control, body weight reduction, and long-term safety. Second, the inclusion of only Chinese participants limits broader applicability of the findings to other racial or ethnic populations. Third, the exclusion of participants who discontinued early from the primary analysis, which was based on a modified FAS, may have introduced bias and potentially overestimated treatment effects. It is worth noting, however, that half of the early discontinuations were due to withdrawal of consent (Part A: 2/4 [50%]; Part B: 3/6 [50%]), rather than lack of efficacy or gastrointestinal AEs. These exploratory findings, therefore, require confirmation in larger trials employing robust methods for handling missing data. Resource availability Lead contact Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Dr. Wei Chen (weichen45@126.com). Materials availability This trial did not generate new unique reagents. There are restrictions to the availability of GZR18 due to ongoing clinical development and intellectual property considerations. GZR18 will be made available on request subject to review of a specific research proposal. Researchers should submit a proposal outlining the scientific rationale and intended use to the lead contact. Requests will be jointly evaluated by the lead contact and the sponsor (Gan & Lee Pharmaceuticals). Approved researchers must complete a material transfer agreement prior to receiving the compound. Commercial applications and independent clinical use of GZR18 are strictly prohibited without a separate licensing agreement. Data and code availability •The trial protocol and other supporting materials are available within this article and its supplemental information. De-identified individual participant data reported in this trial are not publicly available due to ethical and regulatory restrictions. However, requests for data access for academic, non-commercial use purposes can be submitted to the lead contact. All requests will be reviewed by the lead contact and the sponsor, Gan & Lee Pharmaceuticals, within two weeks of submission. Approved requests will require a signed data access agreement with the sponsor prior to data release. The trial protocol and other supporting materials are available within this article and its supplemental information. De-identified individual participant data reported in this trial are not publicly available due to ethical and regulatory restrictions. However, requests for data access for academic, non-commercial use purposes can be submitted to the lead contact. All requests will be reviewed by the lead contact and the sponsor, Gan & Lee Pharmaceuticals, within two weeks of submission. Approved requests will require a signed data access agreement with the sponsor prior to data release. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments This trial was funded by Gan & Lee Pharmaceuticals. The authors thank the trial participants and the trial site staff; Dr. Zhong-Ru Gan of Gan & Lee Pharmaceuticals for his contribution to this trial; Yue Li, Tian Xie, and Anshun He of Gan & Lee Pharmaceuticals for medical writing of the manuscript; and Williams Azubike and Wang Chai for their critical review of the manuscript. Author contributions M. Liu and W.C. contributed to the study conception and design. M. Liu, X.W., M. Li, E.Y., A.Y., M.Y., R.D., G.Q., P.L., C.L., and Y.C. performed the investigation and data collection. M. Liu and W.C. analyzed and interpreted the data. M. Liu, J.Z., L.Z., and W.C. drafted the manuscript. All authors critically reviewed and approved the final version for submission. Declaration of interests M. Liu, X.W., M. Li, E.Y., A.Y., M.Y., R.D., G.Q., P.L., C.L., and Y.C. received research funding from Gan & Lee Pharmaceuticals, during the conduct of the trial. W.C. is the shareholder of Gan & Lee Pharmaceuticals. J.Z. and L.Z. are employees of Gan & Lee Pharmaceuticals. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERBiological samplesHuman plasma and serumPatients participating in the studyN/AChemicals, peptides, and recombinant proteinsGZR18Gan & Lee PharmaceuticalsPMID: 35718129; 40028667PlaceboGan & Lee PharmaceuticalsPMID: 35718129; 40028667Software and algorithmsSAS version 9.4SAS Institutehttps://www.sas.com/ Experimental model and study participant details This multicenter, randomized, double-blind, placebo-controlled phase 1b/2a clinical trial was conducted at 15 sites across China to evaluate the safety, pharmacokinetics (PK), and efficacy of GZR18 injection in Chinese adult patients with type 2 diabetes mellitus (T2DM). This trial was prospectively registered on Chinadrugtrials.org.cn (CTR20221509; June 16, 2022) prior to the enrollment of the first participant (July 20, 2022) and later on ClinicalTrials.gov (NCT06256523; February 5, 2024) to enhance its international visibility. The trial was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki, with approval obtained from the ethics committees at all participating sites. All participants provided written informed consent prior to enrollment. The trial comprised two independent parts, Part A and Part B. Part A included a dose-escalation period (0.5–4 mg) and an efficacy exploratory period, while Part B further assessed the safety, PK, and efficacy of GZR18 at higher dose levels (1.5–13 mg). The inclusion criteria were as follows: 1. Age between 18 and 65 years (inclusive, based on the date of signing the informed consent); both male and female participants are eligible. 2. Diagnosis of T2DM according to the 1999 World Health Organization (WHO) diagnostic and classification criteria for diabetes. 3. Patients with T2DM and inadequate glycemic control through diet and exercise alone and/or suboptimal use of oral anti-diabetic drugs (e.g., metformin, α-glucosidase inhibitors, or sodium-glucose cotransporter-2 [SGLT-2] inhibitors). Suboptimal use was defined as either not adhering to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition),28 or having used anti-diabetic drugs for no more than 2 weeks in the 3 months before screening and no use of anti-diabetic drugs in the month immediately preceding screening. 4. Screening glycated hemoglobin (HbA1c) level ≥7.0% and ≤10.0%. 5. Fasting plasma glucose (FPG) < 13.9 mmol/L at screening. 6. Body mass index (BMI) ≥18.5 kg/m2 and ≤35.0 kg/m2 at screening. 7. No plans for pregnancy from the time of signing informed consent until 3 months after the last dose, and willingness to use effective contraception. Female participants of childbearing potential must have a negative pregnancy test at screening. 8. Patients must fully understand the purpose, nature, methods, and possible adverse reactions of the trial, be willing to voluntarily participate, communicate effectively with the investigators, and comply with all trial requirements. They must also be willing and able to perform self-monitoring of blood glucose (SMBG) and maintain accurate records in a diary. The exclusion criteria were as follows: 1. Diagnosis of non-T2DM, such as type 1 diabetes mellitus. 2. Fasting C-peptide level <0.3 nmol/L. 3. Use of any dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, thiazolidinediones (TZDs), and/or glucagon-like peptide-1 (GLP-1) analogs within 3 months prior to screening. 4. Use of insulin therapy for more than 14 consecutive days within the year prior to screening (insulin treatment during pregnancy is not subject to this restriction). 5. Treatment with growth hormone, diuretics, or other medications that may affect insulin levels within 6 months prior to screening. 6. Abnormal serum immunological tests with clinical significance (e.g., Hepatitis B Surface Antigen [HBsAg], hepatitis C virus antibody [HCV-Ab], human immunodeficiency virus antibody [HIV-Ab], or syphilis screening). 7. Lactating women. 8. History of drug abuse or positive drug abuse screening (urine test) within the past year. 9. History of diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketotic diabetic coma within the past 6 months 10. History of unstable or treated proliferative diabetic retinopathy, maculopathy, severe diabetic neuropathy, intermittent claudication, or diabetic foot within the past 6 months 11. History of severe hypoglycemia (Level 3 hypoglycemia) within the past 6 months, or 3 or more hypoglycemic events (blood glucose ≤3.9 mmol/L) within the past month, or recurrent hypoglycemia-related symptoms. 12. Severe trauma, infection, or surgery that may affect glycemic control within the past month. 13. Blood donation or significant blood loss (>400 mL) or blood transfusion within 3 months prior to screening. 14. Suspected active infections (e.g., active tuberculosis, pneumonia, urinary tract infection, etc.). 15. Surgery within the past 2 months that may lead to unstable body weight, or use of non-diabetic drugs that affect body weight, or participation in a weight loss program (not in the maintenance phase). 16. Uncontrolled hypertension, defined as average systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg at screening. 17. History of severe cardiovascular events (e.g., myocardial infarction, unstable angina, acute cerebrovascular events, peripheral vascular disease) requiring hospitalization or with residual symptoms within the past 6 months 18. History of acute or chronic pancreatitis, symptomatic gallbladder disease (e.g., multiple gallstones), pancreatic injury, or other high-risk factors for pancreatitis. Also excluded if screening reveals elevated serum amylase or lipase ≥1.5 times the upper limit of normal, or if clinically significant abnormalities are present. 19. Calcitonin levels ≥50 ng/L (pg/mL) at screening. 20. History of medullary thyroid cancer, multiple endocrine neoplasia (MEN) type 2A or 2B, or other malignancies. 21. Uncontrolled hyperthyroidism or hypothyroidism, unless stabilized on thyroid hormone replacement therapy for at least 3 months prior to screening. 22. Clinically significant gastrointestinal abnormalities (e.g., gastric outlet obstruction), serious chronic gastrointestinal diseases (e.g., active ulcers within the past 6 months), long-term use of drugs that affect gastrointestinal motility, or gastrointestinal surgery within the past 6 months deemed inappropriate by the investigator. 23. Blood disorders (e.g., aplastic anemia, myelodysplastic syndrome, thalassemia, sickle cell anemia, hemolytic anemia), or any condition causing hemolysis or red blood cell instability (e.g., malaria, allergic purpura). 24. Severe psychiatric disorders or ongoing use of psychiatric medications. 25. Known allergy to any active ingredient of the study drug (GLP-1 or GLP-1 analogs). 26. Contraindications to the use of metformin. 27. History of organ transplantation or other acquired or congenital immune system disorders. 28. Any of the following: presence of a pacemaker at screening; second- or third-degree atrioventricular block, long QT syndrome, or QTc interval ≥450 ms (calculated using Fridericia formula) on 12-lead electrocardiogram (ECG); New York Heart Association (NYHA) class III or IV heart failure; or other clinically significant cardiac abnormalities as judged by the investigator. 29. Clinically significant abnormalities on physical examination as determined by the investigator. 30. Acute or chronic hepatitis, or laboratory findings meeting any of the following: alanine aminotransferase (ALT) ≥2.5 × ULN, aspartate aminotransferase (AST) ≥2.5 × ULN, fasting triglycerides (TG) > 5.7 mmol/L (500 mg/dL); estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 (CKD-EPI equation). 31. Participation in any other drug or device clinical trial within 3 months prior to screening. 32. Excessive alcohol consumption within the past 6 months: >14 units per week for males and >7 units per week for females (1 unit = 360 mL beer, 150 mL wine, or 45 mL of 40% distilled spirits). 33. Clinically significant findings on chest X-ray or abdominal ultrasound (e.g., liver, gallbladder, pancreas) requiring intervention as determined by the investigator. 34. Any condition that, in the investigator’s opinion, may compromise the participant’s ability to provide informed consent or adhere to the trial protocol, or may affect the study results or patient safety. 35. Any other condition deemed inappropriate for trial participation by the investigator. Minor differences exist in the presentation of inclusion and exclusion criteria across the trial protocol, the prospective registration, and the retrospective registration; this variation arises from the distinct formatting and submission requirements of the respective registration platforms, with no change to the scientific rationale or target population. A total of 71 participants were included in the FAS: 36 in Part A and 35 in Part B. In Part A, the mean (standard deviation [SD]) age was 53.6 (11.5) years in the GZR18 group and 53.0 (10.1) years in the placebo group; the proportion of males was 40.7% and 66.7%, respectively. In Part B, the corresponding values were 54.8 (10.1) years versus 49.7 (11.6) years for age, and 69.2% versus 55.6% for male participants. Method details Randomization and Masking Eligible patients were randomized to receive either GZR18 or placebo in a 3:1 ratio using an interactive web response system. The randomization sequences were computer-generated, and the randomization numbers were assigned sequentially upon enrollment. A double-blind design was employed throughout the trial to minimize bias. Both investigators and participants were blinded to treatment assignments. The investigational products (IP), GZR18 and placebo, were identical in appearance, packaging, and administration. Unblinding prior to the database lock was strictly regulated and permitted only in medical emergencies. The randomization scheme was securely stored, and the treatment allocations were not disclosed to the trial team or participants until trial completion, ensuring the integrity of the trial. Intervention Part A and Part B were conducted sequentially, each with a distinct dose-escalation design (Figure S1). Part A included a 2-week screening period, a 26-week treatment period, and a 3-week safety follow-up period (conducted from July 20, 2022, to September 26, 2023). During the 26-week treatment period, participants received GZR18 or placebo once-weekly, starting at 0.5 mg and escalating to 1 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, and 4.0 mg. Each dose level was maintained for 1 to 4 weeks, with escalation contingent on safety assessments. During the trial, a protocol amendment (V2.0, September 16, 2022) was implemented to introduce an efficacy exploration period. Participants who tolerated the highest dose of 4.0 mg continued on this dose for an additional 8 weeks of efficacy exploration, leading to a total of 12 weeks of treatment at the 4.0 mg dose. Based on the favorable safety profile observed in the first-in-human trial and Part A, Part B was designed with a broader dose-escalation range. Part B included a 2-week screening period, a 23-week treatment period, and a 3-week safety follow-up period (conducted from December 29, 2022, to September 28, 2023). During the 23-week treatment period, participants received once-weekly subcutaneous injections of GZR18 or placebo, starting at 1.5 mg and escalating to a maximum dose of 13 mg, with increments occurring every 1 to 4 weeks. To ensure participant safety during dose escalation, additional safety assessments were conducted prior to each dose escalation starting at 5 mg. Patients with inadequate glycemic control following GZR18 treatment were eligible for rescue therapy with metformin as a safety measure. The final dosage, timing, and dosing regimen of metformin were determined by the investigator based on participants’ clinical status. Throughout the trial, all participants received standardized lifestyle intervention under the guidance of investigators, including dietary counseling aiming for an energy deficit of approximately 400–500 kcal/day and a physical activity program of at least 150 min of moderate-intensity exercise per week, in accordance with Chinese guidelines for T2DM management.28,29 Adherence was monitored and reinforced by the investigators at each visit. Outcomes and assessments For both Part A and Part B, the primary endpoints were the safety and tolerability, assessed through the incidence of adverse events (AEs) and serious adverse events (SAEs), including gastrointestinal AEs, hypoglycemia, and injection site reactions. AEs were graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and categorized according to the Medical Dictionary for Regulatory Activities system organ classes and preferred terms. Treatment-emergent adverse events (TEAEs) were monitored from the time of informed consent through the end of the safety follow-up period. The severity of TEAEs (grade 1 to 5) and the relationship between an event and the IPs were assessed by the investigators based on prespecified criteria. Hypoglycemia was classified as level 1 (blood glucose <3.9 mmol/L and ≥3.0 mmol/L), level 2 (blood glucose <3.0 mmol/L) and level 3 (a severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery, irrespective of glucose levels). Other safety assessments included changes in vital signs, clinical laboratory parameters (including lipase, amylase and calcitonin level measures), and electrocardiograms at the end of treatment. Immunogenicity was monitored by measuring titers of antidrug antibodies and neutralizing antibodies. In Part A, the primary endpoint additionally included the change in HbA1c from baseline to week 26, as assessed at a central laboratory. Secondary endpoints in both parts included PK assessments of GZR18 trough concentrations, as well as changes from baseline to the end of treatment in key efficacy parameters, including lipid profiles (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, TG) and SMBG. Part A also assessed the proportion of participants who achieved HbA1c targets below 7.0% and 6.5% or lower at week 26. Part B additionally included the change in HbA1c from baseline to week 23. Exploratory endpoints in both parts included changes from baseline in FPG, body weight, BMI, waist circumference, and the proportion of participants requiring rescue therapy or discontinuing the trial due to hyperglycemia. In addition, Part A assessed changes in HbA1c during the 4 mg dose period from week 14 to week 26. Quantification and statistical analysis No formal sample size calculation was performed in the present trial. The sample size was determined based on data from preclinical studies and the phase 1a clinical trial of GZR18. Information from similar investigational or marketed GLP-1 analogs, particularly data from the phase 2 clinical trial of semaglutide (NCT00696657),30 also informed the sample size determination. Considering the proportion of participants who withdrew or had non-evaluable outcomes, a total of 36 participants were planned to be randomized in each part, with 27 assigned to GZR18 and 9 to placebo. The safety analysis set (SS) included all participants who received at least one dose of the IP. The full analysis set (FAS) included all randomized participants who received at least one dose of the IP and had at least one post-baseline efficacy measurement. The pharmacokinetic analysis set (PKS) included all participants who received at least one dose of GZR18 and had at least one valid plasma concentration-time record. The primary analysis for the primary efficacy endpoint (change from baseline in HbA1c) was performed on the modified FAS population, which included all randomized participants with HbA1c data at week 26 (Part A) or week 23 (Part B). No imputation was performed for missing data. Other continuous efficacy endpoints were analyzed using the same approach as the primary analysis for the primary efficacy endpoint. For continuous endpoints, the mean change from baseline and standard deviation were calculated for each group. The estimated treatment difference between GZR18 and placebo was calculated as the simple difference between these means, with the corresponding 95% confidence interval (CI) calculated using Welch’s t test. For categorical endpoints, the proportion of participants achieving HbA1c targets was calculated as the number of participants who met the target at the end of treatment divided by the total number of participants in the FAS population. To assess the robustness of the findings, a post-hoc sensitivity analysis for the primary efficacy endpoint was performed using a mixed-model for repeated measures (MMRM) in the FAS population. The MMRM model included treatment, sex, visit, baseline HbA1c, baseline BMI, and treatment-by-visit interaction as fixed effects, utilizing all available longitudinal data under a missing-at-random assumption (sex information was self-reported by participants and verified by the investigator at enrollment). Safety outcomes were summarized descriptively. All statistical analyses were performed using SAS version 9.4. Additional resources This clinical trial has been registered on Chinadrugtrials.org.cn (CTR20221509; http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?keywords= CTR20221509) and ClnicalTrials.gov (NCT06256523; https://clinicaltrials.gov/study/NCT06256523). Published: June 19, 2026 Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2026.102874. Contributor Information Ming Liu, Email: mingliu@tmu.edu.cn. Wei Chen, Email: weichen45@126.com. Supplemental information Document S1. Figures S1–S4, and Tables S1–S6 Data S1. Trial protocol and the consort checklist, related to STAR Methods Document S2. Article plus supplemental information References Associated Data Supplementary Materials Document S1. Figures S1–S4, and Tables S1–S6 Data S1. Trial protocol and the consort checklist, related to STAR Methods Document S2. Article plus supplemental information Data Availability Statement •The trial protocol and other supporting materials are available within this article and its supplemental information. De-identified individual participant data reported in this trial are not publicly available due to ethical and regulatory restrictions. However, requests for data access for academic, non-commercial use purposes can be submitted to the lead contact. All requests will be reviewed by the lead contact and the sponsor, Gan & Lee Pharmaceuticals, within two weeks of submission. Approved requests will require a signed data access agreement with the sponsor prior to data release. The trial protocol and other supporting materials are available within this article and its supplemental information. De-identified individual participant data reported in this trial are not publicly available due to ethical and regulatory restrictions. However, requests for data access for academic, non-commercial use purposes can be submitted to the lead contact. All requests will be reviewed by the lead contact and the sponsor, Gan & Lee Pharmaceuticals, within two weeks of submission. Approved requests will require a signed data access agreement with the sponsor prior to data release. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.